News
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Immuron.
RELATED STOCKHEAD STORIES
News
Lunchtime ASX small cap wrap: Who’s calling all the right shots today?
Health & Biotech
Health: Great day for Paradigm as knee data drops and $78m cap raise opens
Health & Biotech
Immuron’s diarrhoea solution pushes revenue to record level
Health & Biotech
No crap: Immuron is one step closer to an anti-gastro pill
Health & Biotech
Big Pharma is watching as Immuron edges towards trial results
Health & Biotech